EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3 EMBER-3 trial were unveiled at the SABCS 2024 conference, presenting critical insights into advanced breast cancer treatment. This global, open-label trial investigated the efficacy and safety of Imlunestrant, an oral endocrine therapy, for ER-positive, HER2-negative advanced breast cancer patients. Key … Continue reading EMBER-3 Reveal: Imlunestrant – Standalone Star or Team Player with Abemaciclib?